Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Comparison of protein biomarker profile in tears from eyes of healthy subjects and dry eye disease patients using novel Olink® Proteomics Technology
Author Affiliations & Notes
  • Mitalee Tamhane
    Clinical Pharmacology, AbbVie Inc, Irvine, California, United States
  • Scott Gladstein
    Discovery and Exploratory Statistics, AbbVie Inc, North Chicago, Illinois, United States
  • Vivian Zhao
    Quantitative Translational and ADME Sciences, AbbVie Inc, California, United States
  • Lisa Borbridge
    Quantitative Translational and ADME Sciences, AbbVie Inc, California, United States
  • Katherine S Held
    Ophthalmology Research, AbbVie Inc, Irvine, California, United States
  • Xin Huang
    Discovery and Exploratory Statistics, AbbVie Inc, North Chicago, Illinois, United States
  • Jie Shen
    Clinical Pharmacology, AbbVie Inc, Irvine, California, United States
  • Mayssa Attar
    Bausch & Lomb Incorporated, New Jersey, United States
  • Footnotes
    Commercial Relationships   Mitalee Tamhane AbbVie, Code E (Employment); Scott Gladstein AbbVie, Code E (Employment); Vivian Zhao AbbVie, Code E (Employment); Lisa Borbridge AbbVie, Code E (Employment); Katherine Held AbbVie, Code E (Employment); Xin Huang AbbVie, Code E (Employment); Jie Shen AbbVie, Code E (Employment); Mayssa Attar Bausch and Lomb, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6565. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mitalee Tamhane, Scott Gladstein, Vivian Zhao, Lisa Borbridge, Katherine S Held, Xin Huang, Jie Shen, Mayssa Attar; Comparison of protein biomarker profile in tears from eyes of healthy subjects and dry eye disease patients using novel Olink® Proteomics Technology. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6565.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The etiology of Dry Eye Disease (DED) is multifactorial impacting tear quality and associated with ocular surface inflammation. Elevated inflammatory cytokines and chemokines in tears have been correlated to clinical endpoints and/or disease severity. While only a small volume is available for sampling, tears have the advantage of being proximal to the ocular surface and are ideal to evaluate biomarkers using non-invasive techniques. The purpose of this research was to compare levels of 45 inflammatory protein markers in tear samples collected from healthy and DED patient eyes. A novel bioanalytical platform for tear biomarker analysis was applied to determine distinct baseline biomarker profile in these 2 populations.

Methods : Tear samples were collected from DED patients and healthy subjects in 2 separate studies utilizing similar tear collection techniques. Approximately 3-5 microlitre of tears were collected into capillary tubes and analyzed using a targeted 48-plex Olink cytokine panel. The unique Proximity Extension Assay (PEA) approach with qPCR readout and dual recognition by DNA-coupled antibodies enabled multiplexed immunoassays of proteins using low tear volume. The Mann-Whitney U test was performed to compare the distributions of biomarkers from healthy subjects vs DED patients. Correlation analysis and variance component analysis were used to evaluate the impact of multiple factors on biomarker values, including sample dilution, collection eye, and multiple collections.

Results : The novel Olink platform was effectively used to determine 45 inflammatory protein markers in tear samples. Biomarker analysis of healthy vs. DED tear samples demonstrated that levels of key inflammatory markers (IL-1B, IL-6, IL-10, IL-17c, IFNγ, and TNFα) were higher in DED vs. healthy subject eyes. In addition, there was an impact of sample dilution (2-fold vs. 4-fold vs. 8-fold) on data for certain markers indicating that collection and analysis method optimization is needed for future use.

Conclusions : To our knowledge this is the first time that Olink platform technology was successfully used for such a comprehensive evaluation of biomarker profile in tears from healthy subjects and DED patients, demonstrating the utility of this platform for future tear biomarker analysis.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×